Phase II study of XELIRI with bevacizumab as second-line therapy for metastatic colorectal cancer -Beyond Progression Disease of capecitabine and bebacizumab
Not Applicable
Completed
- Conditions
- Colorectal Cancer
- Registration Number
- JPRN-UMIN000006877
- Lead Sponsor
- Gunma University Graduate School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method